Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Filer	Shares	Latest Filing Date	Previously owned	Change	Share-Type	Market Value
Casdin Capital, Llc	3.21M	2023-08-14	3.21M	0	Shares	10.13M
Dafna Capital Management Llc	1.31M	2023-08-14	1.31M	0	Shares	4.13M
Baker Bros. Advisors Lp	1.15M	2023-08-14	1.15M	0	Shares	3.63M
Avidity Partners Management Lp	1.11M	2023-08-14	1.27M	-157.20K	Shares	3.51M

NASDAQ:IPSC

Century Therapeutics, Inc.

Last Close

2.38

26/07 20:00

Market Cap

199.42M

Beta: -

Volume Today

151.06K

Avg: 173.42K

PE Ratio

−1.92

PFCF: −2.40

Institutional trades

Institutional Ownership

Current holdings institutionals